Smoothing a contract pathway through uncertainty: In conversation with Neal Masia
Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump administration this year.
Tune into today’s podcast for an exploration of the potential scenarios Masia mused might arise, as well as his insights on the 340B Program, PBMs, and risk-based contracts.
You can listen to episode 210 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
--------
30:30
--------
30:30
FH25: On the future of health, with Frontiers Health Chairman Roberto Ascione
In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione.
Ascione - a serial entrepreneur & thought leader in health innovation and digital health, global executive, CEO and founder of Healthware Group, and President of Health Innovation at EVERSANA – talks about his favourite memory from Frontiers Health, as well as how his work outside of the conference both informs and is informed by it. Finally, he contemplates what will define the future of health.
Listen to this and other episodes from the Frontiers Health limited series here.
--------
12:44
--------
12:44
Allosteric small molecule therapies in PD, with Gene Mack
As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space.
Mack discusses the company’s progress in this field, and explores where next in terms of the unmet needs of Parkinson’s disease and the potential of this specific area of R&D in the future.
You can listen to episode 209a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
--------
20:01
--------
20:01
FH25: Jessica DaMassa on hosting, hype, and health innovation
As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has had a front-row seat to the events evolution over the last decade.
In this episode of the pharmaphorum podcast’s special Frontiers Health anniversary series, DaMassa joins Deep Dive editor, Eloise McLennan, for a behind-the-scenes look at what it takes to run the show – both on and off stage. She reflects on her very first visit to Frontiers Health, her evolution from conference-floor reporter to main-stage moderator, and why flexibility, curiosity, and a healthy sense of humour are essential tools for interviewing some of the biggest names in healthcare.
A self-described “health tech gossip,” DaMassa shares what she’s most looking forward to at this year’s event, how she prepares for interviews with top leaders across pharma and digital health, and why hype doesn’t always equal impact when it comes to innovation.
--------
29:41
--------
29:41
Improving ROI on AI investments and data quality, with Dr Jay Anders
Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements.
In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the only way organisations can solve all three of those problems is by first solving data quality issues.
Anders talks about this data quality crisis, and the financial and operational impacts of the current situation, and explains why providers must ensure clinical data is validated, cleaned, and optimised.
You can listen to episode 208a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Ireland